Sentynl Signs Deal With Fortress’ Cyprium For ‘De-Risked’ Rare Disease Drug

 
• By Alaric DeArment

Deal Snapshot: Sentynl will pay $20m in upfront and regulatory milestone payments through FDA approval, while Cyprium will retain 100% ownership of the priority review voucher.

Handshake of businessmen
Sentynl signed a development and asset purchase agreement for Cyprium's CUTX-101 for Menkes disease, which has approved therapy • Source: Shutterstock

More from R&D

More from Scrip